Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer
Authors
Keywords
-
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-07-15
DOI
10.1007/s10549-021-06143-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
- (2021) L.A. Emens et al. ANNALS OF ONCOLOGY
- Resistance to Checkpoint Inhibition in Cancer Immunotherapy
- (2020) Luisa Barrueto et al. Translational Oncology
- Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
- (2019) Peter Schmid et al. JOURNAL OF CLINICAL ONCOLOGY
- Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
- (2018) Y Bareche et al. ANNALS OF ONCOLOGY
- Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
- (2018) L. Gerratana et al. CANCER TREATMENT REVIEWS
- Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC).
- (2018) Rebecca Dent et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
- (2018) Kamal Pandey et al. INTERNATIONAL JOURNAL OF CANCER
- Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2017) Sung-Bae Kim et al. LANCET ONCOLOGY
- A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors
- (2016) Cristina Saura et al. Cancer Discovery
- Absolute Assignment of Breast Cancer Intrinsic Molecular Subtype
- (2014) Eric R. Paquet et al. JNCI-Journal of the National Cancer Institute
- Targeting PI3K/Akt/mTOR Signaling in Cancer
- (2014) Camillo Porta et al. Frontiers in Oncology
- Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
- (2013) J. Lin et al. CLINICAL CANCER RESEARCH
- Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors
- (2012) James F. Blake et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Induction of Akt Activity by Chemotherapy Confers Acquired Resistance
- (2009) Wei-Chien Huang et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises
- (2008) Timothy A Yap et al. CURRENT OPINION IN PHARMACOLOGY
- Activation of Akt as a Mechanism for Tumor Immune Evasion
- (2008) Kyung Hee Noh et al. MOLECULAR THERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now